{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451607504
| IUPAC_name = 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine
| image = MT-45 svg.svg
| width = 180

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = Class A
| legal_US = 
| legal_DE = Anlage II
| routes_of_administration =  [[oral administration]] [[rectal administration]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 52694-55-0
| CAS_supplemental = 52694-52-7 (S) enantiomer
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 431865
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| synonyms = MT-45, IC-6
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 381935

<!--Chemical data-->
| C=24 | H=32 | N=2
| molecular_weight = 348.523 g/mol
| smiles = c3ccccc3CC(c2ccccc2)N(CC1)CCN1C4CCCCC4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C24H32N2/c1-4-10-21(11-5-1)20-24(22-12-6-2-7-13-22)26-18-16-25(17-19-26)23-14-8-3-9-15-23/h1-2,4-7,10-13,23-24H,3,8-9,14-20H2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = IGBRRSIHEGCUEN-UHFFFAOYSA-N

}}

'''MT-45''' ('''IC-6''') is an [[opioid]] [[analgesic]] drug invented in the 1970s by [[Dainippon Pharmaceutical Co.]]<ref>{{ cite patent
 | country = US
 | number = 3957788
 | status = patent
 | title = 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and their salts
 | pubdate = 1975-15-01
 | gdate = 1976-18-05
 | inventor = Haruki Nishimura, Hitoshi Uno, Kagayaki Natsuka, Noriaki Shimokawa, Masanao Shimizu, Hideo Nakamura
}}</ref> It is chemically a 1-substituted-4-(1,2-diphenylethyl)[[piperazine]] derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of [[morphine]], with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug [[lefetamine]]).<ref name="pmid1195277">{{cite journal |vauthors=Natsuka K, Nakamura H, Uno H, Umemoto S |title=Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities. 1 |journal=Journal of Medicinal Chemistry |volume=18 |issue=12 |pages=1240–4 |date=December 1975 |pmid=1195277 |doi= 10.1021/jm00246a014|url=}}</ref><ref name="pmid962421">{{cite journal |vauthors=Nakamura H, Shimizu M |title=Comparative study of 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine and its enantiomorphs on analgesic and othe pharmacological activities in experimental animals |journal=Archives Internationales de Pharmacodynamie et de Thérapie |volume=221 |issue=1 |pages=105–21 |date=May 1976 |pmid=962421 |doi= |url=}}</ref> It has been used as a [[lead compound]] from which a large family of potent opioid drugs<ref>US Patent 4080453</ref> have been developed, including full agonists, partial agonists, and antagonists at the three main [[opioid receptor]] subtypes.<ref name="pmid722735">{{cite journal |vauthors=Natsuka K, Nakamura H, Negoro T, Uno H, Nishimura H |title=Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities. 2. Structure-activity relationships of 1-cycloalkyl-4-(1,2-diphenylethyl)piperazines |journal=Journal of Medicinal Chemistry |volume=21 |issue=12 |pages=1265–9 |date=December 1978 |pmid=722735 |doi= 10.1021/jm00210a017|url=}}</ref><ref name="pmid106119">{{cite journal |vauthors=Shimokawa N, Nakamura H, Shimakawa K, Minami H, Nishimura H |title=Studies on analgesic agents. 1.1a Preparation of 1,2-diphenyl-2-(4-substituted 1-piperazinyl)ethanol derivatives and structure-activity relationships |journal=Journal of Medicinal Chemistry |volume=22 |issue=1 |pages=58–63 |date=January 1979 |pmid=106119 |doi= 10.1021/jm00187a014|url=}}</ref><ref name="pmid6107365">{{cite journal |vauthors=Nakamura H, Ishii D, Yokoyama Y, Motoyoshi S, Natsuka K, Shimizu M |title=Analgesic and other pharmacological activities of a new narcotic antagonist analgesic (−)-1-(3-methyl-2-butenyl)-4-[2-(3-hydroxyphenyl)-1-phenylethyl]-piperazine and its enantiomorph in experimental animals |journal=The Journal of Pharmacy and Pharmacology |volume=32 |issue=9 |pages=635–42 |date=September 1980 |pmid=6107365 |doi= 10.1111/j.2042-7158.1980.tb13020.x|url=}}</ref><ref name="pmid6319898">{{cite journal |vauthors=Nozaki M, Niwa M, Imai E, Hori M, Fujimura H |title=(1,2-Diphenylethyl) piperazines as potent opiate-like analgesics; the unusual relationships between stereoselectivity and affinity to opioid receptor |journal=Life Sciences |volume=33 Suppl 1 |issue= |pages=431–4 |year=1983 |pmid=6319898 |doi= 10.1016/0024-3205(83)90534-9|url=}}</ref><ref name="pmid3656354">{{cite journal |vauthors=Natsuka K, Nakamura H, Nishikawa Y, Negoro T, Uno H, Nishimura H |title=Synthesis and structure-activity relationships of 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives having narcotic agonist and antagonist activity |journal=Journal of Medicinal Chemistry |volume=30 |issue=10 |pages=1779–87 |date=October 1987 |pmid=3656354 |doi= 10.1021/jm00393a017|url=}}</ref><ref name="pmid10748722">{{cite journal |vauthors=Natsuka K, Nishikawa Y, Nakamura H |title=Roles of two basic nitrogen atoms in 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives in production of opioid agonist and antagonist activities |journal=Chemical & Pharmaceutical Bulletin |volume=47 |issue=12 |pages=1790–3 |date=December 1999 |pmid=10748722 |doi= 10.1248/cpb.47.1790|url=}}</ref>

Recreational use of MT-45 has been associated with hearing loss and unconsciousness.<ref>{{cite journal | journal = Clinical Toxicology | title = MT-45, a new psychoactive substance associated with hearing loss and unconsciousness | date = 2014 | volume = 52 | issue = 8 | pages = 901–904 | doi = 10.3109/15563650.2014.943908 |author1=A. Helander |author2=M. Bäckberg |author3=O. Beck  |last-author-amp=yes | pmid=25175898}}</ref>

MT-45 became a class A drug in the UK on 11 March 2015<ref>{{cite web | url=https://www.gov.uk/government/publications/circular-0032015-a-change-to-the-misuse-of-drugs-act-1971-control-of-mt-45-and-44-dmar | title=Circular 003/2015: a change to the Misuse of Drugs Act 1971: control of MT-45 and 4,4’-DMAR | publisher=UK Home Office | date=20 February 2015 | accessdate=11 March 2015}}</ref>

MT-45 is banned in the Czech Republic.<ref>{{cite web | url=http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | title=Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení  vlády č. 463/2013 Sb.) | publisher=Ministerstvo zdravotnictví | language=Czech}}</ref>

The Canadian [[Controlled Drugs and Substances Act]] was amended in 2016 to include the substance as a Schedule I substance. Possession without legal authority can result in maximum 7 years imprisonment. Further, [[Health Canada]] amended the ''Food and Drug Regulations'' in May, 2016 to classify MT-45 as a restricted drug.<ref>[http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18)]</ref> Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug in Canada.

==See also==
* [[AH-7921]]
* [[AD-1211]]
* [[Diphenidine]]
* [[Ephenidine]]
* [[Fluorolintane]]
* [[IC-26]]
* [[Lanicemine]]
* [[Lefetamine]]
* [[Methoxphenidine]] (MXP)
* [[Remacemide]]

== References ==
{{Reflist|2}}

{{Opioidergics}}

[[Category:Synthetic opioids]]
[[Category:Piperazines]]
[[Category:Mu-opioid agonists]]
[[Category:Diarylethylamines]]
[[Category:Designer drugs]]